Skip to main content

Advertisement

Table 2 Multivariate analysis of predictors of progression-free survival in patients with DLBCL controlled by Revised International Prognostic Index

From: MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells

Variable HR Traning cohort (95% CI) P value HR Validation cohort (95% CI) P value
R-IPI 12.087 2.684–54.472 0.001 1.916 1.261–2.911 0.002
miR155 7.035 1.497–33.053 0.013 2.230 1.183–4.202 0.013